uk.reuters.com

uk.reuters.com
Share

uk.reuters.com

 •  December 21, 2017

BOSTON (Reuters) - North Carolina sued Insys Therapeutics Inc (INSY.O) on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic. FILE PHOTO: The billionaire founder of Insys Therapeutics Inc. John Kapoor, exits the federal court...

uk.reuters.com

 •  September 22, 2017

BOSTON (Reuters) - Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40.1 million to resolve investigations into its marketing and sales of an expensive cholesterol drug, U.S. authorities said on Friday. The settlements will resolve long-running investigations into Aegerion, a subsidiary of Canada’s Novelion Therapeutics...

uk.reuters.com

 •  September 21, 2017

(Reuters Health) - In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market. A new analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done. Dr. Steven...

uk.reuters.com

 •  July 26, 2017

(Reuters Health) - The percentage of Americans sickened as a result of medication errors outside of healthcare facilities doubled between 2000 and 2012, according to research highlighting the need for better labeling and dose management. Medication mistakes outside of hospitals and other healthcare facilities - mostly at home - led to the deaths of...

uk.reuters.com

 •  April 4, 2017

GSK Plc is voluntarily recalling more than 593,000 Ventolin asthma inhalers from U.S. hospitals, pharmacies, retailers and wholesalers due to a defect that may cause them to deliver fewer doses of the medicine than indicated, the British drugmaker said on Tuesday. The company said it had received an elevated number of product complaints about a...

uk.reuters.com

 •  March 3, 2017

REUTERS/Eddie Keogh (BRITAIN - Tags: SCIENCE TECHNOLOGY HEALTH) - RTR4M60H (Reuters Breakingviews) - Drugmakers could lump Britain with a withdrawal problem. They aren’t publicly threatening to pull staff out of the UK, as the automotive and financial industries have done. But Britain’s looming exit from the European Union gives them renewed...

uk.reuters.com

 •  February 23, 2017

The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday. The priority review covers expanded use of Zykadia (ceritinib) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic...

uk.reuters.com

 •  February 14, 2017

A combination treatment from GlaxoSmithKline for melanoma, the deadliest form of skin cancer, has been delayed in Europe after regulators said they needed more information. Britain's biggest drugmaker said on Wednesday it had withdrawn its application and would re-submit its filing for the combined use of Tafinlar, also known as dabrafenib, and...

uk.reuters.com

 •  February 14, 2017

EU antitrust regulators are set to fine Johnson & Johnson (JNJ.N) and Novartis NOVN.VX next month as part of a crackdown against deals delaying the sale of cheaper generic medicines, two people familiar with the matter said on Friday. The sanction, the second against so-called pay-for-delay deals after fines against Lundbeck (LUN.CO) and eight...

uk.reuters.com

 •  February 14, 2017

Some U.S. doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration. India supplies about 40 percent of generic and over-the-counter drugs used in the United States, making it the second-biggest supplier after Canada. In recent...